Scholarlink

<p>Non-small cell lung cancer (NSCLC) is a prevalent form of lung cancer, primarily including adenocarcinomas and squamous cell carcinomas. Advances in targeted therapies have significantly improved NSCLC treatment. In this study, we developed a multifunctional fluorescent imaging nanodrug delivery system using fructose as a natural cross-linker due to its biocompatibility and low toxicity. The incorporation of zinc phthalocyanine-perfluorinated resin (ZnPc-PFR) into chitosan-fructose (CH-Fru) resulted in a nanocomposite with superior fluorescent properties and high loading capacity for compound 1, creating CH-Fru@ZnPc-PFR@1. Furthermore, the combination of compound 1 and gefitinib formed the CH-Fru@ZnPc-PFR@1@Gefitinib composite system, which demonstrated a synergistic effect in inhibiting NSCLC cell proliferation. This study not only developed an effective nanodrug delivery system but also highlighted the potential therapeutic benefits of combining compound 1 with gefitinib for lung cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of Polymer-Based Fluorescent Nanocomposites for Synergistic Inhibition of Non-Small Cell Lung Cancer with Gefitinib

  • 期刊论文

  • 发表日期：

    2025年2月24日

查看全文
  • Hao Li,
  • Jie Yang,
  • Rongrong Sun,
  • Youwei Zhang

摘要

Non-small cell lung cancer (NSCLC) is a prevalent form of lung cancer, primarily including adenocarcinomas and squamous cell carcinomas. Advances in targeted therapies have significantly improved NSCLC treatment. In this study, we developed a multifunctional fluorescent imaging nanodrug delivery system using fructose as a natural cross-linker due to its biocompatibility and low toxicity. The incorporation of zinc phthalocyanine-perfluorinated resin (ZnPc-PFR) into chitosan-fructose (CH-Fru) resulted in a nanocomposite with superior fluorescent properties and high loading capacity for compound 1, creating CH-Fru@ZnPc-PFR@1. Furthermore, the combination of compound 1 and gefitinib formed the CH-Fru@ZnPc-PFR@1@Gefitinib composite system, which demonstrated a synergistic effect in inhibiting NSCLC cell proliferation. This study not only developed an effective nanodrug delivery system but also highlighted the potential therapeutic benefits of combining compound 1 with gefitinib for lung cancer treatment.